Objective  To investigate the impact of clinicopathologic characteristics and therapies on the prognosis of primary cervical non-Hodgkin's lymphoma.

  Methods  Ten patients with primary cervical non-Hodgkin's lymphoma (PCNL), who were enrolled in our hospital from November 1996 to October 2016 were studied retrospectively and the overall survival rate of disease was calculated by Kaplan-Meier survival analysis. The objective was to analyze the therapeutic effect and prognosis of different clinical stages and different treatment methods of the disease.

  Results  Eight patients died and 2 survived. The overall survival time was 5-153 months, the median survival time was 22 months, the 1 year survival rate was 58.3%, the 2 year survival rate was 46.7%, and the 5 year overall survival rate was 23.3%. In the early stage of lymphoma after year 1, 2, and 5, survival rates were 100%, 80%, and 40%, respectively. One year survival rate was 25% for patients with a stage higher thanⅢ; 2-year and 5-year survival rates were 0 and 3%, respectively. In the radiotherapy group, survival was 22 months and in the chemotherapy group, including 1 patient who received 6 cycles of chemotherapy, survival was 153 months. The other 2 patients discontinued treatment after 1 cycle of chemotherapy and their survival was 5 and 37 months, respectively. The survival in 2 cases with combined chemoradiotherapy was 5 and 12 months, respectively. There were 2 patients who were treated with surgery, and their survival was 11 and 118 months, respectively.

  Conclusions  The clinical stage has a great impact on the prognosis of patients with primary cervical lymphoma. For treatment, early stage patients can choose either minor surgery or chemotherapy, and the effect of single chemotherapy is not necessarily lower than that of combined chemoradiotherapy in the advanced stage. The factors were analyzed to provide a basis for future clinical treatment for PCNL patients.